Correction to: Communications Medicine https://doi.org/10.1038/s43856-022-00163-y, published online 29 August 2022.
An author, Luciana Madeira da Silva (LMdS), had inadvertently been omitted from the author list of this article. This author has now been added and the author list is as follows: ‘Rodney P. Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Bradley J. Monk, Thomas J. Herzog, Robert L. Coleman, Luisa Manning, Gladice Wallraven, Staci Horvath, Ernest Bognar, Neil Senzer, Scott Brun, John Nemunaitis’.
LMdS is affiliated with the Mitchell Cancer Institute, Division of Gynecologic Oncology, University of South Alabama, Mobile, USA.
The Author Contributions section has been updated to include LMdS and is now as follows: ‘RPR was responsible for conceptualization, methodology, investigation, resources, writing – review and editing. LS and MT were responsible for conceptualization, methodology, validation, formal analysis, investigation, resources, writing – original draft, review and editing. LMdS was responsible for methodology, data generation, investigation, writing – editing. AW was responsible for methodology, supervision, and writing – review and editing. BJM, TJH, RLC, NS and SB were responsible for supervision and writing – review and editing. LM, GW, SH and EB contributed to investigation, resources and writing – review and editing. JN was responsible for conceptualization, investigation, formal analysis and writing – original draft, review and editing.’
These changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rocconi, R.P., Stanbery, L., Tang, M. et al. Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Commun Med 3, 63 (2023). https://doi.org/10.1038/s43856-023-00290-0
Published:
DOI: https://doi.org/10.1038/s43856-023-00290-0